Questcor Provides Updated New Paid Prescript... (his table. About 5% of the prescriptions...)

Questcor Provides Updated New Paid Prescription Trends

Date:9/10/2011

his table. About 5% of the prescriptions referenced for a specific indication are for related conditions.

(3) A new prescription may or may not represent a new patient or a new therapy for the patient receiving the prescription. We use business rules to determine whether a prescription should be classified as new for counting purposes. From time to time, we may modify these rules.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, for which Acthar is approved as both a maintenance therapy and to treat exacerbations. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Re
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
2. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
3. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
4. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
5. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
6. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
7. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
8. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
9. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
10. Questcor Pharmaceuticals Selects BDO USA as its Auditor
11. Questcor Reports 2010 Financial Results

Post Your Comments:

(Date:6/19/2013)... 19, 2013 NextDocs announced today that ... research organization, at DIA 2013 , the Drug ... present case studies that explore best practices for making ... trial master file (eTMF) systems. Sharon ... alongside Krystyna Kowalczyk , executive vice president of ...

(Date:6/19/2013)... June 19, 2013 Finesse Solutions, Inc, a ... sciences process applications, announced the launch of its ... cell culture and fermentation. The 3L glass vessels ... of Finesse bioreactors and are designed to optimize ... are fully compatible with all Finesse G3Lab controllers, ...

(Date:6/19/2013)... , June 19, 2013 ... recently added DrugPatentWatch to its extensive ... ) (Logo: http://photos.prnewswire.com/prnh/20130128/590935) ... information on pharmaceutical, drug patents and ... the critical business functions of patent ...

Breaking Medicine Technology:NextDocs and Novella to Present on eTMF at DIA 2013 2 Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2 Drug Patent Watch 2 Drug Patent Watch 3

[0] NextDocs and Novella to Present on eTMF at DIA 2013 [0] Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation [0] Drug Patent Watch

... to be held on Wednesday, August 6, 2008 at 8:00 ... ... 5 Isolagen(TM), Inc. (Amex:,ILE) announced today positive top-line efficacy and safety ... the,Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles.,Each study, conducted ...

... WHIPPANY, N.J., Aug. 5 Nexgen Spine, a ... treatment of,degenerative disc disease, announced today that it ... Lumbar Artificial Disc in the European,Union., "We ... has,received CE mark approval," said Alastair Clemow, Ph.D., ...

Cached Medicine Technology:Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 2 Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 3 Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 4 Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant 5 Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2

Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc

(Date:6/20/2013)... June 20, 2013 Footwear etc. is pleased ... USA , and has received many new styles and colors ... models, and models never before introduced in the U.S. The ... loyal following of MBT customers. , MBT shoes feature a ... on sand. This sole also provides outstanding shock absorption, and ...

(Date:6/20/2013)... June 20, 2013 TASC, a ... announced a new service to deal with funding ... the Patient Protection & Affordable Care Act (PPACA), ... health outcomes, clinical effectiveness, and appropriateness" of different ... and conduct its own, with funding in part ...

(Date:6/20/2013)... David Icke, the highly visible alternative researcher and ... , Fresh from the Bilderburg fringe festival and the ... to launch ‘The Peoples Voice’ TV and Radio station by ... opportunity for journalists to cover the stories and investigations that ... globe. , Because this station is for the people, ...

(Date:6/20/2013)... Sydney, Australia (PRWEB) June 20, 2013 ... , research was presented recently, that can show similarities ... food. This could explain the current global obesity ... be addicted to food just as one can be ... Neuroscience and Applied Cognitive Science at the University of ...

(Date:6/20/2013)... 2013 HIPAA One aims ... through a HIPAA Security Risk Analysis using the simplest ... extends the reach of all the HIPAA programs by ... Privacy Officers, security professionals, and members of the Healthcare ... policies and procedures. The new Web site features ...

Breaking Medicine News(10 mins):Health News:Footwear etc. Announces New MBT Shoes for Spring/Summer 2 Health News:TASC Service Helps Employers Handle New Burdens for Health Reimbursement Arrangement Plans 2 Health News:Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic 2 Health News:Modern Compliance Solutions Launches a New Web Site Promoting the Industry-Proven, Web-Based HIPAA One Security Solution 2

[0] Footwear etc. Announces New MBT Shoes for Spring/Summer [0] TASC Service Helps Employers Handle New Burdens for Health Reimbursement Arrangement Plans [0] David Icke to Launch Global TV and Radio Station Called The People's Voice [0] Research Suggests That Unhealthy Food Addiction Could Explain Global Obesity Epidemic [0] Modern Compliance Solutions Launches a New Web Site Promoting the Industry-Proven, Web-Based HIPAA One Security Solution

... - Sanofi Pasteur committed to increasing its seasonal ... production capacity in the U.S. -SWIFTWATER, Pa. and ... vaccines division of sanofi-aventis Group (EURONEXT: SAN and ... the U.S. Food and Drug Administration (FDA) has ...

... May 6 Funds in the FY 2010 budget aimed ... to improve access to outpatient physical therapy services for Medicare ... Therapy Association (APTA). S.Con.Res.13 ... 2009-FY 2014, was passed April 29 by the House of ...

... Mary Bono Mack (CA-45) and Nita Lowey (NY-18) ... and well-being of American youth by reintroducing the ... The bipartisan legislation, broadly supported by such organizations ... cross-sector collaboration for improving the health of young ...

... Team Finance LLC (the "Company"), today announced results for the ... uncollectibles ("revenue less provision") in the first quarter of 2009 ... first quarter of 2008. Same contract revenue less provision ... million in the same period a year ago. In ...

... bare-metal version, studies show , , WEDNESDAY, May 6 ... stents are less likely to become blocked again than ... and heart attacks is virtually identical between the two ... show. , The Swedish results eliminate concerns raised by ...

... of those hospitalized in U.S. is 15, CDC says , , ... of U.S. cases of swine flu continue to be mild, ... be atypically young, federal health officials said Wednesday. , The ... which is younger than occurs with regular seasonal flu, Dr. ...

U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility Funds in 2010 Budget Could Increase Access to Care for Medicare Beneficiaries Bono Mack, Lowey Introduce Bill To Improve the Health of Youth Team Finance LLC Announces First Quarter 2009 Results Drug-Coated Stents Better at Keeping Arteries Open Younger Age of More Severe Swine Flu Cases Worries Experts

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Hepatitis C Virus RNA Qualitative PCR Hepatitis C Virus Antibody with Reflex to Supplemental RIBA Hepatitis C Virus Antibody Hepatitis C Virus Antibody (RIBA), Supplemental